Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics completes $316.25 million convertible notes offering due 2032

Neutral Impact 4 of 5 financing Written later

NeoGenomics completed a $316.25 million offering of 0.75% convertible senior notes due 2032, including an option exercised by the initial purchasers for $41.25 million. The company also used about $263.19 million to repurchase about $276.0 million of its 0.25% convertible notes due 2028, and it used about $28.7 million of offering proceeds for capped call transactions meant to reduce potential dilution.

Key points

  • Notes total $316.25 million, with interest of 0.75% per year payable semiannually, maturing July 1, 2032
  • Initial conversion price is about $14.16 per share, a 35.0% premium to the $10.49 closing price on June 16, 2026
  • Up to 30,147,733 shares may be issued on conversion; the company may settle conversions in cash, shares, or both
  • Concurrent repurchase of about $276.0 million of 2028 notes for about $263.19 million, including accrued interest

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECJun 22, 2026, 5:17 PM ET
Accession number0001077183-26-000037

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 22, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.